RevolKa Ltd., a biotech company specializing in protein engineering, has joined forces with the La Jolla Institute for Immunology (LJI) to collaborate on creating antigens for next-generation vaccines. The aim of this partnership is to address unmet medical needs in the field of infectious diseases.

RevolKa’s innovative technology platform, aiProtein, combines protein engineering with artificial intelligence (AI) to predict sequences for evolved protein function. This technology, integrated with LJI’s expertise in immunology, is set to revolutionize the development of vaccines.

While the financial details of the collaboration have not been disclosed, the strategic alliance between RevolKa and LJI marks a significant step towards advancing vaccine research and development.

Stay tuned for more updates on this groundbreaking partnership in the biotech and immunology sectors.